Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + bortezomib + dexamethasone in lenalidomide-refractory multiple myeloma (KMM 2405)
KCT0011099Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Oct 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide in multiple myeloma (MM), sponsored by Boryung. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0011099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011099.